lookingbad
Iron
- Joined
- Nov 2, 2025
- Posts
- 37
- Reputation
- 18
Why you should run NAAAS only and how?
We know that even low dosage test will induce aromatisation and thus we'll have a minimum intracellular e2 proliferating around the growth plates cartilage binding to the ERα, the estrogen receptor that is more potent for bone effects and has low neurological/brain properties --> risking growth plates closure even at really low E2 levels making it a risk option to run aromatising AAS. Furthermore ERβ signal(estrogen receptor needed for BDNF increase and neuroprotection + sligthly modulating bone effects, but a lot less potent than ERa on bones) will be really low or none at all, making that even riskier by compromising the antioxidant properties of estrogen (really bad for everyone, especislly people running 19-NORs)so the best thing we can run is
Non aromatising AAS (NAAAS) + Raloxifene (SERM acting mildly well only on the ERb making useful and a good neuroprotector when not using any aromatising AAS and furthermore for Raloxifene activates ERα (the actual receptor that signal growth plates to maturate and thus close) much less strongly than estradiol and does not produce the same closure signal
ERβ modulates ; ERα is the main driver
ERα ≈ 80–90% ERβ ≈ 10–20%
Using androgens this way:
(NAAAS + RALOXIFENE as ERb signal for neuroprotection) would slows growth plates closure a lot more compared to when: test dosage is low-high (even 40-80mg/week) even if local/serum e2 are low because ERα signalling is less present in the NAAAS subject than the LOW TEST DOSAGE subject and Neuroprotection would be more valid in the NAAAS subject.
Now, combining what we said we can use Trenbolone IGF-1 affinity in tissue/bones (and mitigating the neurological side effects with raloxifene + drugs that increase dopaminergic and protective seratonergic effects + other ancillaries for health) with high dosage HGH (with maybe insulin for upregulating the receptors even more) with other drugs for height (PTHA's + FGFR3i + HDAC modulation) we can drastically improve Adult Final Height.
STUDIES:
Use that information at your own responsibility.
We know that even low dosage test will induce aromatisation and thus we'll have a minimum intracellular e2 proliferating around the growth plates cartilage binding to the ERα, the estrogen receptor that is more potent for bone effects and has low neurological/brain properties --> risking growth plates closure even at really low E2 levels making it a risk option to run aromatising AAS. Furthermore ERβ signal(estrogen receptor needed for BDNF increase and neuroprotection + sligthly modulating bone effects, but a lot less potent than ERa on bones) will be really low or none at all, making that even riskier by compromising the antioxidant properties of estrogen (really bad for everyone, especislly people running 19-NORs)so the best thing we can run is
Non aromatising AAS (NAAAS) + Raloxifene (SERM acting mildly well only on the ERb making useful and a good neuroprotector when not using any aromatising AAS and furthermore for Raloxifene activates ERα (the actual receptor that signal growth plates to maturate and thus close) much less strongly than estradiol and does not produce the same closure signal
ERβ modulates ; ERα is the main driver
ERα ≈ 80–90% ERβ ≈ 10–20%
Using androgens this way:
(NAAAS + RALOXIFENE as ERb signal for neuroprotection) would slows growth plates closure a lot more compared to when: test dosage is low-high (even 40-80mg/week) even if local/serum e2 are low because ERα signalling is less present in the NAAAS subject than the LOW TEST DOSAGE subject and Neuroprotection would be more valid in the NAAAS subject.
Now, combining what we said we can use Trenbolone IGF-1 affinity in tissue/bones (and mitigating the neurological side effects with raloxifene + drugs that increase dopaminergic and protective seratonergic effects + other ancillaries for health) with high dosage HGH (with maybe insulin for upregulating the receptors even more) with other drugs for height (PTHA's + FGFR3i + HDAC modulation) we can drastically improve Adult Final Height.
STUDIES:
- In the study tamoxifene was compered to raloxifene, tamoxifene was stronger on paper:
-directly inhibited osteoclast differentiation:
-directly reduced bone resorption:
https://pubmed.ncbi.nlm.nih.gov/17420779/
so by knowing that tamoxifene can be used in teenager for blocking local estrogens in growth plates and raloxifene is weaker, raloxifene could be used for the same context.
- Neurological-dopaminergic benefits of raloxifene:
https://pubmed.ncbi.nlm.nih.gov/39799793/
- TRENBOLONE POTENCY ON IGF-1 RECEPTORS:
https://pubmed.ncbi.nlm.nih.gov/2707149/
https://www.sciencedirect.com/science/article/abs/pii/S0739724010001001
Use that information at your own responsibility.